1. ApoA-V is a novel regulator of lipid metabolism in cardiomyocytes. PMID: 29530023
2. e0192740 PMID: 29425239
3. novel role for ApoA5 as a modulator of susceptibility to diet-induced liver and muscle insulin resistance through regulation of ectopic lipid accumulation in liver and skeletal muscle. PMID: 25548259
4. The data suggest that apoA-V suppresses the production of chylomicrons, playing a previously unknown role in lipid metabolism that may contribute to the postprandial hypertriglyceridemia associated with apoA-V deficiency. PMID: 25617349
5. Data indicate that apolipoprotein A5 (APOA5) plays a role in the central regulation of food intake. PMID: 23650188
6. Gene transfer of human apoA-V improves the severe hypertriglyceridemia phenotype of apoa5 null mice. PMID: 23329134
7. Intravenously injected apoA-V rHDL significantly lowers plasma TG in an apoA-V deficient mouse model and requires gpihbp1. PMID: 20966404
8. Data show that livers from apolipoprotein A-V (APOA-V) transgenic mice contain significantly higher amounts of triglycerides than livers from wild-type or apoA-V knockout mice, suggesting that apoA-V influences intrahepatic triglyceride levels. PMID: 20153840
9. Preferential association of apoA-V(1-146) with murine plasma HDL, but not with VLDL, suggests that particle size is a determinant of its lipoprotein binding specificity. PMID: 19825998
10. a role of ApoA-V in regulating levels of circulating triglycerides and cholesterol. PMID: 12135615
11. Review. APOA5 represents a newly discovered gene involved in triglyceride metabolism in both humans and mice whose mechanism of action remains to be deciphered. PMID: 12615678
12. apoAV lowers plasma TG by both reducing the hepatic VLDL-TG production rate and by enhancing the lipolytic conversion of TG-rich lipoproteins PMID: 15090553
13. ApoAIV is a direct target gene of Liver X receptors (LXRs) that may contribute to the antiatherogenic effect of LXR activation PMID: 15131258
14. apo A-IV and apo A-V are positive acute-phase proteins in mouse HDL. PMID: 15306172
15. apoAV reduces triglyceride levels by guiding VLDL and chylomicrons to proteoglycan-bound LPL for lipolysis PMID: 15774484
16. in staggerer mice, apoa5 gene is not affected by RORalpha PMID: 15790933
17. absence of apoAV slows lipolysis of triglyceride rick lipoprotein and the removal of their remnants by regulating their apoproteins content after secretion PMID: 16166565
18. These data demonstrate that (i) apoA-V expression decreases early during the APR due to changes in mRNA stability, and (ii) during the APR apoA-V is not inversely related to plasma TG levels in mice and humans. PMID: 16325772
19. APOA5 could also influence cholesterol homeostasis and probably play a role in hypertriglyceridemia associated with diabetes and inflammation. PMID: 16448983
20. and metabolic consequences and phenotype of the three APOA5 mutations reported to date, which lead to premature truncations of apoAV are described PMID: 17222847
21. These data suggest that in addition to its TG-lowering effect, apoA-V plays a significant role in modulating HDL maturation and cholesterol metabolism. PMID: 17438339
22. oxidized fatty acids may act through an APOA5/APOClll mechanism that contributes to lowering of TG levels other than PPAR* induction PMID: 18243209
23. the apoCIII enhancer contributes to the maintenance of an active chromatin subdomain of the apoAI/CIII/AIV genes, but not apoAV PMID: 18678879
24. Data suggest that higher plasma apolipoprotein AV levels reflect an increased demand for plasma triglyceride hydrolysis under normal physiological conditions. PMID: 19141870
25. These findings are consistent with the presence of a functional PPAR-binding element in the promoter of the human APOA5 gene; this element is however degenerate and non-functional in the corresponding mouse Apoa5 sequence. PMID: 19362162

顯示更多

收起更多

KEGG: mmu:66113

STRING: 10090.ENSMUSP00000034584

UniGene: Mm.29738